Grifols (NASDAQ:GRFS) Sets New 12-Month Low – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $7.26 and last traded at $7.2870, with a volume of 409443 shares traded. The stock had previously closed at $7.40.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wall Street Zen downgraded Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Weiss Ratings raised Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Finally, Zacks Research lowered shares of Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Grifols presently has an average rating of “Reduce” and a consensus target price of $10.00.

Grifols Price Performance

The stock has a fifty day moving average price of $7.90 and a 200-day moving average price of $8.50. The company has a market cap of $4.92 billion, a PE ratio of 38.03, a price-to-earnings-growth ratio of 0.28 and a beta of 0.65. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.47 and a quick ratio of 0.85.

Grifols (NASDAQ:GRFS) last issued its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. The business had revenue of $2.32 billion during the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%. On average, equities analysts expect that Grifols, S.A. will post 1.06 earnings per share for the current year.

Grifols Dividend Announcement

The firm also recently announced a special dividend, which will be paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd will be paid a dividend of $0.0945 per share. The ex-dividend date of this dividend is Thursday, July 2nd. Grifols’s payout ratio is 73.68%.

Institutional Trading of Grifols

Several institutional investors have recently made changes to their positions in GRFS. JPMorgan Chase & Co. lifted its position in Grifols by 31.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,488,294 shares of the biotechnology company’s stock worth $24,783,000 after buying an additional 600,118 shares in the last quarter. Integrated Quantitative Investments LLC acquired a new position in shares of Grifols in the third quarter worth $1,361,000. Diversify Wealth Management LLC purchased a new stake in shares of Grifols during the third quarter worth $1,156,000. Hennion & Walsh Asset Management Inc. boosted its position in Grifols by 31.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 478,769 shares of the biotechnology company’s stock valued at $4,476,000 after purchasing an additional 113,539 shares during the last quarter. Finally, Capital World Investors grew its stake in Grifols by 5.9% in the third quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock valued at $228,344,000 after purchasing an additional 1,273,391 shares in the last quarter.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.